Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.49 |
| ▸ | FNTB | P49356 | 5/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708779 | 0.88 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL6708777 | 0.86 | FNTA (0.57) | FNTAFNTBCYP11B1CYP11B2MAPT | |
| SCHEMBL6711144 | 0.81 | FNTA (0.46) | FNTAFNTBPGGT1B | |
| SCHEMBL6710804 | 0.81 | FNTA (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL6710981 | 0.81 | FNTA (0.49) | FNTAFNTBMAPTPGGT1B | |
| SCHEMBL6710993 | 0.81 | FNTA (0.49) | FNTAFNTBCYP11B1CYP11B2MAPT | |
| SCHEMBL6709653 | 0.80 | MAPT (0.54) | FNTAFNTBMAPT | |
| SCHEMBL6711125 | 0.80 | FNTA (0.47) | FNTAFNTBMAPT | |
| SCHEMBL7090174 | 0.80 | FNTA (0.45) | FNTAFNTBPGGT1B | |
| SCHEMBL6711140 | 0.80 | FNTA (0.51) | FNTAFNTBCYP11B1CYP11B2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | PIERRE FABRE MEDICAMENT (FR) | 2004-05-13 | — | — | US | claimed |
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | PIERRE FABRE MEDICAMENT (FR) | 2004-05-13 | — | — | US | disclosed |
| EP-1324999-A1 | NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030927-A1 | NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | CBR3, CBR1, HCCS | FNTA 194/4885FNTB 48/4885CYP11B1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.